We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$767M
AUM Growth
+$137M
Cap. Flow
+$31.2M
Cap. Flow %
4.08%
Top 10 Hldgs %
34.48%
Holding
123
New
27
Increased
33
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$14.4M
2
CYTK icon
Cytokinetics
CYTK
+$12.9M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.3M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$7.27M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$14.5M
2
TSEM icon
Tower Semiconductor
TSEM
+$8.98M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
CLBT icon
Cellebrite
CLBT
+$8.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Miscellaneous 10.43%
3 Technology 7.55%
4 Utilities 1.93%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.32B
$8.15M 1.06%
752,983
+215,355
+40% +$1.95M
LRCX icon
27
Lam Research
LRCX
$366B
$8M 1.04%
+18,470
New +$5.61M
AMAT icon
28
Applied Materials
AMAT
$346B
$7.98M 1.04%
+11,040
New +$5.09M
TNGX icon
29
Tango Therapeutics
TNGX
$3.84B
$7.95M 1.04%
254,250
-89,313
-26% -$2.21M
NVS icon
30
Novartis
NVS
$310B
$7.83M 1.02%
50,000
+13,000
+35% +$1.95M
VOR icon
31
Vor Biopharma
VOR
$1.43B
$7.67M 1%
416,417
+94,500
+29% +$1.43M
ABBV icon
32
AbbVie
ABBV
$460B
$7.61M 0.99%
30,256
– –
MRK icon
33
Merck
MRK
$376B
$7.53M 0.98%
58,600
+10,000
+21% +$1.17M
JNJ icon
34
Johnson & Johnson
JNJ
$671B
$7.32M 0.96%
28,831
– –
IDYA icon
35
IDEAYA Biosciences
IDYA
$3.86B
$7.32M 0.96%
+196,408
New +$6.01M
IMTX icon
36
Immatics
IMTX
$1.44B
$7.29M 0.95%
720,057
+23,952
+3% +$253K
NVCT icon
37
Nuvectis Pharma
NVCT
$796M
$7.04M 0.92%
+382,945
New +$4.29M
PFE icon
38
Pfizer
PFE
$164B
$6.89M 0.9%
286,000
+100,000
+54% +$2.62M
HRMY icon
39
Harmony Biosciences
HRMY
$2.44B
$6.43M 0.84%
+176,663
New +$5.57M
XENE icon
40
Xenon Pharmaceuticals
XENE
$5.85B
$6.34M 0.83%
105,000
-22,000
-17% -$1.22M
CLYM
41
Climb Bio
CLYM
$838M
$6.31M 0.82%
483,747
+64,500
+15% +$666K
ZBIO
42
Zenas BioPharma
ZBIO
$2.15B
$5.86M 0.76%
230,834
+16,500
+8% +$328K
NVO
43
Novo Nordisk
NVO
$210B
$5.79M 0.75%
120,677
– –
ELVN icon
44
Enliven Therapeutics
ELVN
$4.37B
$5.72M 0.75%
112,765
-40,500
-26% -$1.72M
PRLD icon
45
Prelude Therapeutics
PRLD
$419M
$5.44M 0.71%
1,019,832
+461,493
+83% +$2.01M
GSK icon
46
GSK
GSK
$102B
$5.35M 0.7%
102,000
-20,000
-16% -$1.06M
FBRX
47
DELISTED
Forte Biosciences
FBRX
$5.31M 0.69%
249,693
+64,709
+35% +$1.53M
BIOA
48
BioAge Labs
BIOA
$436M
$5.24M 0.68%
213,671
+127,153
+147% +$2.3M
SRRK icon
49
Scholar Rock
SRRK
$6.81B
$5.18M 0.68%
94,265
– –
MSLE
50
Satellos Bioscience
MSLE
$193M
$5.07M 0.66%
652,590
+163,383
+33% +$1.12M
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sphera Funds Management held 123 positions worth $767M, up 22% from $630M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management deployed $31.2M of net new capital in Q2 2026, opening 27 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 118,800 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Nova, an estimated $14.5M trimmed.

  • Sphera Funds Management's largest Q2 2026 buy was Insmed: 118,800 shares worth $12.7M.
  • Sphera Funds Management added most to Cytokinetics in Q2 2026, an estimated $12.9M increase.
  • Sphera Funds Management's biggest Q2 2026 reduction was Nova, cutting an estimated $14.5M.
  • Sphera Funds Management fully exited Amicus Therapeutics in Q2 2026, selling an estimated $8.72M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $767M portfolio in Q2 2026.
  • Sphera Funds Management opened 27 new positions and closed 18 in Q2 2026.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $767M.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.